Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
Yosuke Kawashima(Sendai Kousei Hospital), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Gyo Asai(Aichi Cancer Center), Kozo Yoshimori(Japan Anti Tuberculosis Association), Kunihiko Kobayashi(Saitama International Medical Center), Shunichiro Iwasawa(Chiba University), Haruhiro Saito(Kanagawa Cancer Center), Ou Yamaguchi(Saitama International Medical Center), Futoshi Kurimoto(Saitama Cancer Center), Koichi Azuma(Kyushu University Hospital), Masahiro Seike(Nippon Medical School Hospital), Yukari Tsubata(Shimane University), Ichiro Nakachi(Saiseikai Utsunomiya hospital), Tatsuro Fukuhara(Miyagi Prefectural Hospital Organization), Hiromi Nagashima(Iwate Medical University), Naoki Furuya(St. Marianna University School of Medicine), Yoshio Tsunezuka(Ishikawa Prefectural Central Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Satoshi Morita(Kyoto University), Masaki Miyazaki(Suita Municipal Hospital), Yuka Fujita, Morihito Okada(Hiroshima University), Toshihiro Nukiwa(Tohoku University), Satoshi Watanabe(Niigata University Medical and Dental Hospital), Kana Watanabe(Miyagi Prefectural Hospital Organization), Koichi Hagiwara(Jichi Medical University)
Institutional Repositories DataBase (IRDB)
January 1, 2022
Cited by 109
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k